Liver Disease
Conditions
Brief summary
This study assesses the safety and tolerability of RTA 402 in patients with liver disease.
Detailed description
RTA 402 is a synthetic triterpenoid that is designed to suppress oxidative stress and inflammatory processes that play a significant role in a wide variety of diseases. It is a potent suppressor of inflammation and oxidative stress. Oxidative stress plays a role in the pathogenesis of hepatitis, and RTA 402 has demonstrated activity in a preclinical model of hepatitis, in addition to other models of inflammation. This is a 28-day, multiple-dose, dose-escalation study. It is anticipated that a total of 3 groups of 8 patients each will be enrolled, in which 6 patients in each group will be randomized to receive RTA 402, and 2 patients per group will be randomized to placebo (3:1). Patients will receive treatment daily for 14 days with a starting dose of 5mg, 25mg, or 50mg. Patients will return for follow up visits on Days 16 and 21, and complete end of study procedures on Day 28.
Interventions
DRUGRTA 402
5 mg oral capsules
Sponsors
Biogen
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Chronic liver disease. * An estimated creatinine clearance of ≥ 60 mL/min. * Serum alanine transaminase (ALT) or aspartate transaminase (AST) elevation must be above the upper limit of normal and below 5 times the upper limit of normal for patients with underlying liver disease; Child-Pugh score 5 to 9 (mild to moderate impairment). * Patient must agree to practice effective contraception during the entire study period. * Patient is willing to avoid strenuous physical activity from 24 hours prior to the study start, throughout the study, and for 2 weeks after the administration of the dose of study drug * Patient is willing to avoid any alcohol consumption for the 24 hours prior to, and the 48 hours after administration of study drug; and avoid excessive alcohol consumption for the duration of the follow-up period. * Patient must be able and willing to sign informed consent form.
Exclusion criteria
* Patient with clinically significant illnesses or recent hospitalization (within 60 days) which could compromise participation in the study in the judgment of the investigator, including: uncontrolled diabetes; active or uncontrolled infection; Confirmed diagnosis of HIV infection; uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or uncontrolled cardiac arrhythmia. * Patient with any other auto immune disease, major chronic inflammatory disease or syndrome requiring significant treatment within the past year. * Patients who are pregnant or breast feeding * Patient receiving or has received any investigational drug within 30 days prior (or is currently using an investigational device) * Patients with prior (within 4 weeks) or concurrent treatment with oral steroids, or protein-based therapy (i.e. TNFa) * Patients with positive urine screen for drugs of abuse except when receiving a prescribed medication for a known indication * Patients with Grade 2 or above hepatic encephalopathy. * Patients who donated blood or experienced a significant blood loss (\>450 mL) within 8 weeks of screening * Patients with a history of bleeding varices within 12 weeks of screening. * Patients with psychiatric illness or other condition that would limit compliance with study requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the safety and tolerability of multiple-dose oral administration of RTA 402 in patients with hepatic dysfunction. | 28 days |
Secondary
| Measure | Time frame |
|---|---|
| To correlate the biological activity of RTA 402 with drug concentration in plasma. | 28 days |
Countries
United States
Outcome results
None listed